Molecular Cancer Therapeutics

Article	Citations
Selected Articles from This Issue	100
Abstract B048: Fibroblast Growth Factor Receptor 2 Alterations in non-Cholangiocarcinoma Gastrointestinal Tumors	85
Abstract C078: DNA Nanocarrier-mediated Co-Delivery of Cisplatin and Silibinin for enhanced treatment of Oral Squamous Cell Carcinoma	65
Abstract A093: VRN110755 Shows Promise with Improved Efficacy in EGFR mutation NSCLC: Highlighting CNS activity, Potency Against Resistant EGFR Mutations, and a Favorable Safety Profile	63
Abstract A042: Evolution of resistance in brain tumors: Effects of the blood brain barrier	62
Abstract B119: FMC-376, a dual inhibitor of ON + OFF states of KRAS G12C, is active in sotorasib resistant PDX models	62
Abstract A043: P-gp overexpression confers resistance to treatment with the antibody-drug conjugate mirvetuximab soravtansine	62
Abstract B086: Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition	59
Abstract A014: Comprehensive genomic and clinicopathologic characterization of ESR1 mutations in Chinese breast cancer patients reveals distinct molecula	59
Abstract B073: Targeted Phenotype Shifting or Killing Tumor Associated Macropages (TAMs) Leading to Effective Upregulation of the Immune System Response to Solid Tumors: A Comprehensive	56
Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)	53
In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation	51
Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death	49
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer	48
Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation	44
Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabd	44
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer	44
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer	44
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas	42
Targeted Nanofitin-drug Conjugates Achieve Efficient Tumor Delivery and Therapeutic Effect in an EGFRpos Mouse Xenograft Model	40
IKS04, a CanAg-Targeting Antibody–Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models	40
Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis	39
Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer	39
Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer	39
Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor	38

Radiation and Chemo-Sensitizing Effects of DNA-PK Inhibitors Are Proportional in Tumors and Normal Tissues	38
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma	37
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers	37
Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma	35
Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors	35
Selected Articles from This Issue	34
Response to Systemic Therapies in Patient-Derived Cell Lines from Primary and Recurrent Adult Granulosa Cell Tumors	33
NAD+ Metabolic Enzyme Inhibitor as Radiosensitizer for Malignant Meningioma and its Modulation of P53 Expression	32
A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer	31
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy	31
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma	29
Olaparib and Radiotherapy Induce Type I Interferon– and CD8+ T Cell–Dependent Sensitization to Immunotherapy in Pancreatic Cancer	29
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors	29
Mechanisms of Response and Resistance to PSMA×CD3 Bispecifics in CD34+ Humanized Mice	29
Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (W	28
Abstract A092: Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer	28
Abstract A128: Identification of peptide inhibitors of KRAS G12D and Q61H mutant protein for cancer therapy	28
Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings	28
Abstract B018: TAK1 blockade induces DNA damage and immunogenic cGAS–STING pathway activation in pancreatic cancer	28
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models	28
Abstract C128: Disrupting the Oncobiosphere: CAF-Targeting Therapy with Penetrium™ Reverses Pseudo-Resistance in Tumors	27
Abstract A032: PTEN protein and lipid phosphatase deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer	27
Abstract A089: UnAcH416 (P2), a selective PRMT1 inhibitor, disrupts tumor cell growth and stress-response pathways	26
Abstract A003: Baseline levels of HIF2 target proteins and response to the HIF2α inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma	26
Abstract B065: Using Mutations in a Dimerization Interface of ERBB4 and ERBB2 to Elucidate the Role of ERBB4-ERBB2 Heterodimers in wild-type BRAF Melanomas	25
Abstract A141: Incidence of pulmonary and hematologic adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled t	25
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma	24
Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates	24
Selected Articles from This Issue	24
MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells	24
Acknowledgement to Reviewers	24
A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism	24
Abstract A131: Sigvotatug vedotin, an integrin-beta 6 directed antibody drug conjugate, demonstrates potent single-agent antitumor activity across NSCLC subtypes and the potential to combine with targ	24
The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years	24
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations	24
IL15/IL15Rα Complex Induces an Antitumor Immune Response following Radiotherapy only in the Absence of Tregs and Fails to Expand Progenitor TCF1+ CD8 T Cells	23
Near-Infrared Photoimmunotherapy Targeting Podoplanin-Expressing Cancer Cells and Cancer-Associated Fibroblasts	23
The role of Siglec-15 in tumor immunity: mechanism and therapy	23
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists	23
Abstract B062: Loss of Flotillin-2 increases Trastuzumab emtansine internalization and cytotoxicity in HER2 amplified cancers	22
Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy	22
Abstract A053: Targeting Acquired Resistance to KRASG12D Inhibitors: designing rationale synergistic treatments	22
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS	22
Abstract B032: Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)	21
Abstract C135: CBL0137 as a promising therapeutic strategy for anaplastic, treatment-emergent neuroendocrine prostate cancer	21
Abstract A016: cfDNA fragmentome predicts cancer treatment response similarly to mutant allele fraction	21
Abstract A054: Evaluation of HER3-targeting ADC patritumab deruxtecan in irinotecan-resistant colorectal cancer PDX models reveals resistance mechanisms and informs rational combination strategies	21
Abstract B064: TRI-611, a selective, CNS-penetrant molecular glue degrader of ALK with anti-tumor activity against preclinical models of ALK-fusion positive non-small cell lung cancer including kinase	21
Abstract C121: Single-cell RNA profiling reveals metastatic capacity of the malignant cells underlying microvascular invasion in patients with hepatocellular carcinoma	21
Abstract C030: Functional characterization of VS-186B, a novel HDAC inhibitor for cancer treatment	21

Abstract A027: First-in-class oral macrocyclic Cyclin D1-selective inhibitors demonstrate anti-tumor activity in Cyclin D1-dependent tumors	20
Abstract C084: The farnesyl transferase inhibitor KO-2806 constrains mTORC1 activity to enhance the antitumor efficacy of mutant-selective PI3Kα inhibitors	20
Abstract A072: KRAS G12C mutation and metastatic colorectal cancer: Are we ready for neo-adjuvant? A case report.	20
Abstract C129: Fostamatinib as a STAT3 inhibitor and potential therapeutic for triple negative breast cancer and high grade serous ovarian cancer	20
Abstract B077: Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity	20
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab	19
Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts	19
PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index	19
Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0	19
Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors	19
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity	19
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer	18
Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells	18
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors	18
Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML	18
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer	18
Selected Articles from This Issue	17
Abstract B090: Radiation-induced oral mucositis to rapidly determine effective radiosensitizing dosing regimens for ATM and DNAPK inhibitors	17
Abstract C088: Intelligent Hit Discovery Platform for Accelerated Cyclic Peptide Radiopharmaceutical Development	17
Abstract B142: EO3001: A novel agent for ARID1A mutant cancers	17
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer	17
Abstract A012: Comparative analysis of circulating variant allele fractions in healthy individuals and patients with solid tumors using an ultra-sensitive liquid biopsy assay MUTE-Seq	17
Abstract C127: Modulating the tumor niche-specific protein corona of nanomedicines for the precision targeting of chemoresistant cells using patient-derived organoids	17
Abstract B061: In vivo benchmarking of trastuzumab deruxtecan (T-DXd) activity in panel of 400 XPDX models	17
Selected Articles from This Issue	17
Abstract A073: Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF -mutated primary and brain met	17
Abstract C055: Incidence of gastrointestinal adverse events in advanced or metastatic cancer patients treated with Datopotamab Deruxtecan: A meta-analysis of phase III randomized controlled trials	17
Abstract B082: Assessment of prevalence and utilization of tumor mutational burden and microsatellite instability in cancer patients at a community cancer center	17
Abstract C048: Chemoproteomic-enabled fragment-based drug discovery target identification in small cell lung cancer	16
The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo	16
Translating Preclinical Studies into the Clinic: Assays and Endpoints Selected to Determine Efficacy	16
Reducing Dietary Protein Enhances the Antitumor Effects of Chemotherapy through Immune-Mediated Mechanisms	16
Abstract B036: A novel PDE10 inhibitor that blocks RAS and β-catenin signaling and enhances tumor immunogenicity with robust activity to inhibit tumor growth and metastasis	16
Cross-resistance of Belinostat and Romidepsin in Non–T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP	16
Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer	16
Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition	15
Targeting DDR2 for Treating Pancreatic Cancer	15
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors	15
All- trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin	15
STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition	15
IMiDs Augment CD3-Bispecific Antibody–Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production	15
Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory	15
Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers	15
Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors	15
Combination of Bremachlorin PDT and Immune Checkpoint Inhibitor Anti–PD-1 Shows Response in Murine Immunological T-cell–High and T-cell–Low PDAC Models	15
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors	15
GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling	15
Selected Articles from This Issue	14
Target-Specific Locked Nucleic Acid Gapmer Decreases Growth and Metastases of Pancreatic Cancer	14
Abstract C106: Validated novel Immuno-therapeutic targets for lung cancer revealed by SpliceIOTM- Innovative platform that identifies disease-specific alternative splicing	14
Abstract B126: The effects of Amaryllidaceae plant constituents narciclasine, lycorine and haemanthamine on chronic lymphocytic leukemia cells	14
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer	14
Selected Articles from This Issue	14
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition	14
Abstract B009: Trial in Progress: Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/ Amplified Gastric/ Gastroesophageal Junction Cancer and	14
Moxidectin Unravels the Role of the Hippo–YAP Pathway in Maintaining Immunity of Glioblastoma Multiforme	14
Selected Articles from This Issue	14
NOC2L Promotes Paclitaxel Resistance in Various Types of Ovarian Cancers by Decreasing NDUFA4 through Histone Acetylation Suppression	14
Abstract A036: Synthetic RNA-guided combinatorial targeting of glioblastoma adaptive resistance: Dual suppression of PI3K-AKT and mesenchymal transition escape pathways	14
Abstract C062: MED12 loss promotes PD-L1–mediated immune evasion and predicts response to immune checkpoint inhibitors in NSCLC	14
Abstract A078: Molecule Glue Profiling Unveils the Dynamics of KRAS-Induced Proximity	13
Abstract A088: Revealing intrinsic ATPase activity in kinases: Implications for drug discovery using ADP-Glo assay	13
Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway	13
Decreased DNA Damage and Improved p53 Specificity of RITA Analogs	13
Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells	13
Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas	13
Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma	13
Abstract B084: Clinical Outcomes and Biomarker Correlates of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Novel Immunotherapies in Phase 1 Trials	13
Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors	13
Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability	13
Current Status and Challenges of Vaccination Therapy for Glioblastoma	13
Tumor Microenvironment Reprogramming Improves Nanomedicine-Based Chemo-Immunotherapy in Sarcomas	13
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies	13
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity	13
Abstract C059: Development of a Differentiated, Best-in-Class Oral Cbl-b Inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy	13
Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors	13
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios	13
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer	13
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma	13
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems	13

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource	13
Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads	13
Abstract C063: Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience	12
Abstract A126: CDR609: A First-in-Class LGR5-targeted T Cell Engager for treatment of Colorectal Cancer and other solid tumors	12
Targeting Transcriptional Cyclin-Dependent Kinases in Cancer	12
Selected Articles from This Issue	12
Abstract A001: Prevalence of Common HLA Class I Alleles in a Spanish Oncology Cohort Prescreened for Early-Phase Trials: Implications for Broadening Access to HLA-Restricted Therapies	12
Abstract C004: ADC screening platform, a useful platform for ADC drug evaluation	12
Abstract B034: A chemoproteomic-enabled phenotypic library screen identifies KIF23 as a novel target in Ewing sarcoma	12
Abstract A123: Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients	12
Abstract A102: Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy Trial	12
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy	12
Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study	12
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis	11
Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer	11
Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy	11
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerabili	11
Augmenting Chemokine CCL21 Enhances the Effectiveness of CTLA4 Blockade Immunotherapy for Head and Neck Squamous Carcinoma	11
Non-Glycosylated, Legumain-Cleavable ISACs Drive Potent Anti-Tumor Immunotherapy via a Bystander Effect	11
Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers	11
CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues	11
Abstract C046: Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study	11
Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes	11
MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma	11
Selected Articles from This Issue	11
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors	11
TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma	11
Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency	11
FOXN Transcription Factors: Regulation and Significant Role in Cancer	11
ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors	11
Vitamin A Metabolism and Resistance of Hepatic Metastases to Immunotherapy	11
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models	10
A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies	10
Abstract A019: Single-cell analysis of tumor population diversity in synovial sarcoma	10
Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specific T Cell Cytotoxicity	10
Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells	10
N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase	10
Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer	10
Abstract A121: Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics	10
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance	10
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy	10
Abstract A040: Resistance to trastuzumab deruxtecan acquired through multifaceted pathway alterations in preclinical models	10
Abstract B094: Modelling ADC sensitivity and mode-of-action in human cancer derived organoids	10
Abstract C124: MCAT™: A 3D Co-Culture Platform for Genome-Wide CRISPR Screening to Identify Stromal-Driven Vulnerabilities in CMS4 Colorectal Cancer	10
Abstract C006: Fitness landscape modeling indicates decreased effectiveness of microtubule assembly targeting drugs in tumors demonstrating chromosomal instability (CIN)	10
First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter	10
Abstract C118: A Non-Canonical role of cGMP Links PDE5A Inhibition to Metastasis Suppression	10
Abstract A049: Impact of Actionable Genomic Alterations (AGA) on the Efficacy of Durvalumab in Patients with Locally Advanced NSCLC Treated with Concurrent Chemoradiotherapy	10
ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance	10
Abstract A116: Characterization of micvotabart pelidotin target binding properties and extracellular payload release	10
Abstract B087: A translational platform of patient-derived xenografts (PDXs) for upper gastrointestinal cancers	10
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model	10
Abstract C120: TACC3 is a driver of metastasis in centrosome-amplified breast cancer	10
Predicting the Abscopal Phenomenon—Letter to the Editor	10
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel	10
Abstract A097: Global pharmacodynamic effects uncovered with AP3 phosphoproteomic profiling of novel WEE1/PKMYT1 inhibitor ACR-2316 reveals the critical importance of PLK1 for ACR-2316’s superior prec	10
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate	9
Selected Articles from This Issue	9
Abstract C100: Therapeutic targeting of microRNA-31 promotes chemosensitivity via ATOX1 in pancreatic ductal adenocarcinoma	9
Abstract A061: Identification and validation of integrin β1 as an in vivo -specific combination partner with MAPK pathway inhibitors in BRAF mutant color	9
Abstract B043: Activation Lethality through the WNT/beta-catenin pathway drives efficacy in colorectal cancer	9
Abstract A037: Coordinated activity between AR-V7 and glucocorticoid receptor drives resistance to androgen receptor signaling inhibition	9
Abstract C051: Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omics data and organoid studies	9
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy	9
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer	9
Abstract C053: Acrivon Therapeutics’ generative ensemble model (KaiSR) accurately predicts and expands proprietary, actionable kinase-substrate relationships globally for the human kinome	9
Abstract A114: Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study	9
Abstract C094: Tumor-associated fibroblasts drive taurine accumulation and radiotherapy resistance in renal cell caecinoma via the CXCL12/CXCR4/SLC6A6 axis	9
Abstract A058: Investigating metformin as a unique therapeutic for KRAS-mutant non-small cell lung cancer	9
A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer	9
Radiation Synergizes with IL2/IL15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity	9
Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites	9
Abstract A007: Is liquid biopsy a reliable surrogate for MSI testing? A concordance study using matched tissue and ctDNA-based NGS	9
Abstract A118: Discovery of HMPL-A251, a first-in-class HER2-directed antibody-targeted therapy conjugate (ATTC) with a novel PI3K/PIKK inhibitor payload	9
Abstract B046: Dimerization of SLFN12 by the PDE3A-SLFN12 complex is required for velcrin-induced toxicity in cancer cells	9
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects	9
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model	9
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors	9
The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells	8
Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations	8
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation	8
Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma	8
The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death	8
Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs	8
Selected Articles from This Issue	8
Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103	8
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers	8
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies	8
Modular Smart Molecules for PSMA-Targeted Chemotherapy	8
Selected Articles from This Issue	8
IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion	8
FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma	8
The Discovery of a Potent PARP1 Inhibitor Senaparib	8
The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review	8
Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies	8